ecancermedicalscience

Review

Unlocking artificial intelligence, machine learning and deep learning to combat therapeutic resistance in metastatic castration-resistant prostate cancer: a comprehensive review

29 Jul 2025
Zainab Haider Ejaz, Reyan Hussain Shaikh, Alizeh Sonia Fatimi, Saqib Raza Khan

Metastatic castration-resistant prostate cancer (mCRPC) remains a formidable clinical challenge despite advancements in therapy. This narrative review explores the role of artificial intelligence (AI), machine learning and deep learning in addressing therapeutic resistance in mCRPC. AI-driven approaches leverage integrated datasets encompassing genomics, proteomics and clinical parameters to uncover molecular mechanisms, predict treatment responses and identify biomarkers of resistance. These methodologies promise personalised treatment strategies tailored to individual patient profiles. However, data heterogeneity and regulatory considerations are challenges that hinder the translation of AI insights into clinical practice. By synthesising current literature, this review examines the progress, potential and limitations of AI applications in combating therapeutic resistance in mCRPC, highlighting implications for future research and clinical implementation.

Related Articles

Rewati Raman Rahul, Nandini Vallath, Kunal Oswal, Ravikant Singh, Kumar Gaurav, Paul Sebastian, Venkataramanan Ramachandranand Arnie Purushottham
Eduardo Cazap, Benjamin O Anderson, Giuseppe Curigliano, Sandeep Sehdev, Fatima Cardoso, Ana Rita Gonzalez, Emad Shash, Cheng-Har Yip, André Mattar, Yanin Chavarri-Guerra, Miriam Mutebi, Yongmei Yin, João Victor Rocha, Ilaria Lucibello, Namita Srivastava